Enzyme Replacement Therapy Market Size & Share, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase); Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency [EPI]); End-user (Hospitals, Infusion Centers & Home Healthcare Settings) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4455
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Companies Dominating the Enzyme Replacement Therapy Landscape

top-features-companies
    • BioMarin
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Leadiant Biosciences, Inc.
    • Pfizer Inc.
    • Sanofi Aventis
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • JCR Pharmaceutical Co., Ltd.
    • AstraZeneca plc
    • Clinigen Limited
    • Teijin Limited 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

 

  •  Teijin Limited announced the immediate availability of Revcovi 2.4 mg for intramuscular injection [Elapegademase (Genetic Recombination)]. With Revcovi 2.4 mg, Japan's first medication for Adenosine Deaminase (ADA) Deficiency, individuals with ADA Deficiency are expected to have improved ADA activity and immune system.

  • Clinigen Limited, a global pharmaceutical Products, and Services company, announced that Clinigen K.K., a fully owned subsidiary of Clinigen located in Tokyo, has gained manufacturing and marketing authorization for Hunterase (Idursulfase-beta) ICV 15mg as part of its strategic relationship with GC Pharma. The clearance of Hunterase ICV in Japan marks its first appearance in any nation globally.

 


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4455
  • Published Date: Feb 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are rise in prevalence of rare disease, growing government spending on healthcare infrastructure, growing cases of Pompe disease, and others.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2033.

Lack of awareness, high cost of enzyme replacement therapy, and stringent reimbursement policies are some of the major factors expected to hinder the growth of the market.

The market in Asia Pacific is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are BioMarin, Leadiant Biosciences, Inc., Pfizer Inc., Sanofi, and more.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, disease, end user, and by region.

The agalsidase beta segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying